Journal of the Neurological Sciences
Volume 223, Issue 2 , Pages 145-148 , 30 August 2004

Decrease in GTP-sensitive high affinity agonist binding of muscarinic acetylcholine receptors in autopsied brains of dementia with Lewy bodies and Alzheimer's disease

  • Kazumasa Shiozaki

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +81-45-787-2667; fax: +81-45-783-2540.
    • Department of Psychiatry, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa , Yokohama 236-0004, Japan
    • ,
  • Eizo Iseki

      Affiliations

    • Department of Psychiatry, Koto Geriatric Medical Center, Juntendo University School of Medicine, 3-3-20 Shinsuna, Koto, Tokyo 136-0075, Japan

Received 20 January 2004 ,Revised 5 May 2004 ,Accepted 6 May 2004.

References 

  1. Shiozaki K, Haga T. Effects of magnesium ion on the interaction of atrial muscarinic acetylcholine receptors and GTP-binding regulatory proteins. Biochemistry. 1992;31(43):10634–10642
  2. Brown D, Chisholm JA, Owens J, Pimlott S, Patterson J, Wyper D. Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging. 2003;30(2):296–300
  3. Dickson DW, Davies P, Mayeux R, Crystal H, Horoupian DS, Thompson A, et al.  Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients. Acta Neuropathol. (Berl.). 1987;75(1):8–15
  4. Liberini P, Valerio A, Memo M, Spano PF. Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?. Trends Pharmacol. Sci. 1996;17(4):155–160
  5. Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, et al.  Lewy bodies and response to tacrine in Alzheimer's disease. Lancet. 1994;343(8890):176
  6. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–1124
  7. Kosaka K. Diffuse Lewy body disease. Intern. Med. 1998;37(1):6–10
  8. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479–486
  9. Shiozaki K, Iseki E, Uchiyama H, Watanabe Y, Haga T, Kameyama K, et al.  Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 1999;67(2):209–213
  10. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J. Neurochem. 1988;50(6):1914–1923
  11. Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 1992;31(1):103–111
  12. Perry EK, Smith CJ, Court JA, Perry RH. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J. Neural Transm., Parkinson's Dis. Dement. Sect. 1990;2(3):149–158
  13. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. 1995;64(4):1888–1891
  14. Ferrari-DiLeo G, Mash DC, Flynn DD. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol. Chem. Neuropathol. 1995;24(1):69–91
  15. Warpman U, Alafuzoff I, Nordberg A. Coupling of muscarinic receptors to GTP proteins in postmortem human brain-alterations in Alzheimer's disease. Neurosci. Lett. 1993;150(1):39–43
  16. Ladner CJ, Celesia GG, Magnuson DJ, Lee JM. Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1995;54(6):783–789
  17. Ladner CJ, Lee JM. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations. Exp. Neurol. 1999;158(2):451–458
  18. Flynn DD, Weinstein DA, Mash DC. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann. Neurol. 1991;29(3):256–262

PII: S0022-510X(04)00145-5

doi: 10.1016/j.jns.2004.05.002

Journal of the Neurological Sciences
Volume 223, Issue 2 , Pages 145-148 , 30 August 2004

Article Tools